ABBVIE INC. vs. Bolt Biotherapeutics, Inc. Common Stock
ABBVIE INC. (ABBV) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABBV | BOLT | |
|---|---|---|
| Market Cap | $466.45 billion | $6.86 million |
| Revenue (TTM) | $64.39 billion | $4.70 million |
| Net Income (TTM) | $6.32 billion | $-28,739,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | BOLT | |
|---|---|---|
| P/E Ratio | 74.56 | — |
| Price / Book | -79.22 | 0.54 |
| Price / Sales | 7.24 | 1.46 |
ABBV and BOLT split the valuation factors evenly.
Profitability
| ABBV | BOLT | |
|---|---|---|
| Net Margin | 9.81% | -611.47% |
| Return on Equity | -107.29% | -227.37% |
ABBV leads on 2 of 2 profitability factors.
Dividend
| ABBV | BOLT | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and BOLT split the dividend factors evenly.
Risk & Sentiment
| ABBV | BOLT | |
|---|---|---|
| Short Interest | 0.85% | 22.62% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, BOLT overview, BOLT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.